- Home
- NVGS vs COGT Comparison
NVGS vs COGT Comparison
Compare NVGS & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVGS
- COGT
- Stock Information
- Founded
- NVGS 1997
- COGT 2014
- Country
- NVGS United Kingdom
- COGT United States
- Employees
- NVGS N/A
- COGT N/A
- Industry
- NVGS Marine Transportation
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- NVGS Consumer Discretionary
- COGT Health Care
- Exchange
- NVGS Nasdaq
- COGT Nasdaq
- Market Cap
- NVGS 1.1B
- COGT 895.8M
- IPO Year
- NVGS N/A
- COGT 2018
- Fundamental
- Price
- NVGS $16.70
- COGT $8.20
- Analyst Decision
- NVGS Strong Buy
- COGT Buy
- Analyst Count
- NVGS 3
- COGT 6
- Target Price
- NVGS $22.00
- COGT $14.17
- AVG Volume (30 Days)
- NVGS 163.2K
- COGT 1.4M
- Earning Date
- NVGS 03-12-2025
- COGT 02-24-2025
- Dividend Yield
- NVGS 1.20%
- COGT N/A
- EPS Growth
- NVGS 13.48
- COGT N/A
- EPS
- NVGS 1.12
- COGT N/A
- Revenue
- NVGS $564,280,000.00
- COGT N/A
- Revenue This Year
- NVGS $0.05
- COGT N/A
- Revenue Next Year
- NVGS $4.76
- COGT N/A
- P/E Ratio
- NVGS $14.91
- COGT N/A
- Revenue Growth
- NVGS 5.99
- COGT N/A
- 52 Week Low
- NVGS $14.55
- COGT $4.28
- 52 Week High
- NVGS $18.18
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- NVGS 61.90
- COGT 49.78
- Support Level
- NVGS $16.51
- COGT $6.60
- Resistance Level
- NVGS $17.25
- COGT $8.72
- Average True Range (ATR)
- NVGS 0.46
- COGT 0.52
- MACD
- NVGS 0.09
- COGT 0.11
- Stochastic Oscillator
- NVGS 70.15
- COGT 75.47
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture).
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.